Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Other Non Operating Income of $285600.0 for Q1 2026, up 149.44% quarter-over-quarter from -$577659.0 in Q4 2022.
Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other Non Operating Income for 6 consecutive years, with $285600.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income changed N/A year-over-year to $285600.0; the TTM figure through Mar 2026 stood at $285600.0 (changed N/A YoY), while the FY2023 annual figure was -$577659.0, up 43.67% from the prior year.
- Other Non Operating Income improved to $285600.0 in Q1 2026 per OTLK's latest filing, from -$577659.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $285600.0 in Q1 2026 and bottomed at -$577659.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285,600.00 |
| Dec 31, 2022 | -577,659.00 |
| Dec 31, 2021 | -1.03 Mn |
| Jun 30, 2020 | 6.16 Mn |
| Dec 31, 2019 | -8.06 Mn |
| Jun 30, 2019 | -423,686.00 |
| Mar 31, 2019 | -183,554.00 |
| Dec 31, 2017 | -1.25 Mn |